NEW YORK, Oct 29 (Reuters) - The Food and Drug Administration has approved Novartis AG's NOVN.VX Afinitor to treat benign brain tumors, Novartis said on Friday.
The drug can be used to treat adults and children with benign brain tumors associated with tuberous sclerosis, a genetic disorder that may cause tumors to form in vital organs.
Prior to the approval, the only option to treat this form of tumor was surgery, according to Novartis.
The approval was based on a 28-patient study which showed that nearly one-third of patients had at least a 50 percent reduction in their largest tumors after six months.
Reporting by Helen Kearney; Editing by Sanjeev Miglani
Our Standards: The Thomson Reuters Trust Principles.